![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C2CD2 |
Gene summary for C2CD2 |
![]() |
Gene information | Species | Human | Gene symbol | C2CD2 | Gene ID | 25966 |
Gene name | C2 calcium dependent domain containing 2 | |
Gene Alias | C21orf25 | |
Cytomap | 21q22.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9Y426 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25966 | C2CD2 | C04 | Human | Oral cavity | OSCC | 1.04e-03 | 2.80e-01 | 0.2633 |
25966 | C2CD2 | C30 | Human | Oral cavity | OSCC | 5.62e-06 | 4.14e-01 | 0.3055 |
25966 | C2CD2 | C43 | Human | Oral cavity | OSCC | 1.42e-07 | 2.09e-01 | 0.1704 |
25966 | C2CD2 | C46 | Human | Oral cavity | OSCC | 2.03e-03 | 1.56e-01 | 0.1673 |
25966 | C2CD2 | C51 | Human | Oral cavity | OSCC | 2.32e-07 | 5.25e-01 | 0.2674 |
25966 | C2CD2 | C06 | Human | Oral cavity | OSCC | 8.18e-03 | 6.51e-01 | 0.2699 |
25966 | C2CD2 | C08 | Human | Oral cavity | OSCC | 1.47e-02 | 3.88e-02 | 0.1919 |
25966 | C2CD2 | EOLP-1 | Human | Oral cavity | EOLP | 1.59e-06 | 1.55e-01 | -0.0202 |
25966 | C2CD2 | NEOLP-1 | Human | Oral cavity | NEOLP | 4.74e-03 | 2.06e-01 | -0.0194 |
25966 | C2CD2 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.49e-04 | 1.44e-01 | -0.0191 |
25966 | C2CD2 | SYSMH3 | Human | Oral cavity | OSCC | 2.08e-17 | 3.70e-01 | 0.2442 |
25966 | C2CD2 | SYSMH5 | Human | Oral cavity | OSCC | 1.00e-03 | 1.13e-01 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C2CD2 | insertion | Frame_Shift_Ins | novel | c.1562_1563insAGGGTTTCACTATGTTGGC | p.Ser522GlyfsTer89 | p.S522Gfs*89 | Q9Y426 | protein_coding | TCGA-EJ-A7NF-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | ||
C2CD2 | SNV | Missense_Mutation | c.442N>T | p.Gly148Cys | p.G148C | Q9Y426 | protein_coding | deleterious(0.02) | benign(0.408) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
C2CD2 | SNV | Missense_Mutation | rs201984634 | c.236N>G | p.Ala79Gly | p.A79G | Q9Y426 | protein_coding | tolerated(0.31) | benign(0.015) | TCGA-BR-8361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
C2CD2 | SNV | Missense_Mutation | c.1414N>A | p.Leu472Ile | p.L472I | Q9Y426 | protein_coding | deleterious(0.03) | benign(0.265) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
C2CD2 | SNV | Missense_Mutation | novel | c.661N>C | p.Gly221Arg | p.G221R | Q9Y426 | protein_coding | tolerated(0.26) | benign(0) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
C2CD2 | SNV | Missense_Mutation | novel | c.2028N>T | p.Lys676Asn | p.K676N | Q9Y426 | protein_coding | tolerated(0.06) | benign(0.286) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |